These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25537684)

  • 21. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor.
    Steinfeld T; Mammen M; Smith JA; Wilson RD; Jasper JR
    Mol Pharmacol; 2007 Aug; 72(2):291-302. PubMed ID: 17478612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ligand competition curves as a diagnostic tool for delineating the nature of site-site interactions: theory.
    Henis YI; Levitzki A
    Eur J Biochem; 1979 Dec; 102(2):449-65. PubMed ID: 527588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of receptor binding displacement curves by a nonhomologous ligand, on the basis of an equivalent competition principle.
    van Zoelen EJ
    Anal Biochem; 1992 Feb; 200(2):393-9. PubMed ID: 1321566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach.
    Packeu A; Wennerberg M; Balendran A; Vauquelin G
    Br J Pharmacol; 2010 Nov; 161(6):1311-28. PubMed ID: 20946109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor.
    Sabatucci A; Tortolani D; Dainese E; Maccarrone M
    Biotechnol Appl Biochem; 2018 Jan; 65(1):21-28. PubMed ID: 28833445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopamine D2 Receptors Dimers: How can we Pharmacologically Target Them?
    Carli M; Kolachalam S; Aringhieri S; Rossi M; Giovannini L; Maggio R; Scarselli M
    Curr Neuropharmacol; 2018 Jan; 16(2):222-230. PubMed ID: 28521704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Receptor binding kinetics equations: Derivation using the Laplace transform method.
    Hoare SRJ
    J Pharmacol Toxicol Methods; 2018; 89():26-38. PubMed ID: 28818556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allosteric modulation of kinases and GPCRs: design principles and structural diversity.
    Lewis JA; Lebois EP; Lindsley CW
    Curr Opin Chem Biol; 2008 Jun; 12(3):269-80. PubMed ID: 18342020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery.
    Christopoulos A
    Nat Rev Drug Discov; 2002 Mar; 1(3):198-210. PubMed ID: 12120504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploration of the orthosteric/allosteric interface in human M1 muscarinic receptors by bitopic fluorescent ligands.
    Daval SB; Kellenberger E; Bonnet D; Utard V; Galzi JL; Ilien B
    Mol Pharmacol; 2013 Jul; 84(1):71-85. PubMed ID: 23604140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allosteric binding cooperativity in a kinetic context.
    Díaz Ó; Martín V; Renault P; Romero D; Guillamon A; Giraldo J
    Drug Discov Today; 2023 Feb; 28(2):103441. PubMed ID: 36372329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular determinants of drug-receptor binding kinetics.
    Pan AC; Borhani DW; Dror RO; Shaw DE
    Drug Discov Today; 2013 Jul; 18(13-14):667-73. PubMed ID: 23454741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Avidity and positive allosteric modulation/cooperativity act hand in hand to increase the residence time of bivalent receptor ligands.
    Vauquelin G; Bricca G; Van Liefde I
    Fundam Clin Pharmacol; 2014 Oct; 28(5):530-43. PubMed ID: 24118041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures.
    Annis DA; Nazef N; Chuang CC; Scott MP; Nash HM
    J Am Chem Soc; 2004 Dec; 126(47):15495-503. PubMed ID: 15563178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Motions of Allosteric and Orthosteric Ligand-Binding Sites in Proteins are Highly Correlated.
    Ma X; Meng H; Lai L
    J Chem Inf Model; 2016 Sep; 56(9):1725-33. PubMed ID: 27580047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allosteric targeting of receptor tyrosine kinases.
    De Smet F; Christopoulos A; Carmeliet P
    Nat Biotechnol; 2014 Nov; 32(11):1113-20. PubMed ID: 25380447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allosteric interactions via the orthosteric ligand binding sites in a constitutive G-protein-coupled receptor homodimer.
    Kukkonen JP
    Pharmacol Res; 2021 Apr; 166():105116. PubMed ID: 32783977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities.
    De Amici M; Dallanoce C; Holzgrabe U; Tränkle C; Mohr K
    Med Res Rev; 2010 May; 30(3):463-549. PubMed ID: 19557759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor.
    Miao Y; Goldfeld DA; Moo EV; Sexton PM; Christopoulos A; McCammon JA; Valant C
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):E5675-84. PubMed ID: 27601651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The kinetics of bivalent ligand-bivalent receptor aggregation: ring formation and the breakdown of the equivalent site approximation.
    Posner RG; Wofsy C; Goldstein B
    Math Biosci; 1995 Apr; 126(2):171-90. PubMed ID: 7703593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.